Business Context and Reporting Period
Company: uniQure N.V.
Filing Type: Form 8-K (Current Report)
Date of Report: November 10, 2025
Reporting Period: Quarter ended September 30, 2025
Context: The filing serves as a notification that the Company issued a press release announcing its financial results for the quarter ended September 30, 2025, and providing a corporate update. The press release is included as Exhibit 99.1.
Key Financial Metrics
The provided Form 8-K text acts as a cover document referencing a press release (Exhibit 99.1) but does not contain specific financial data tables or figures within the body of this filing.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Note: Specific values for revenue, profit, cash flow, margins, debt, and liquidity are not present in the provided filing text. Investors must refer to the referenced Exhibit 99.1 (Press Release) for these details.
Material Changes
The filing text does not explicitly detail material changes versus the prior comparable period. It only confirms the issuance of results for the quarter ended September 30, 2025.
Guidance, Outlook, and Risks
The filing indicates that a "corporate update" was provided alongside the financial results in the referenced press release. However, the specific content regarding guidance, outlook, management commentary, risks, contingencies, or unusual items is not included in the text of this Form 8-K.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 10, 2025) for actual financial figures (revenue, net loss, cash position).
- Verify the specific details of the "corporate update" mentioned in Item 2.02, as this may contain strategic shifts or pipeline updates.
- Confirm the Company's cash runway and burn rate, as these are critical for a biopharmaceutical entity not reporting revenue in this summary.
- Check for any new risk factors or regulatory updates disclosed in the full press release.